Advertisement

Plasmodium falciparum Infection and the Other Human Malarias

  • G. C. Cook
Part of the The Bloomsbury Series in Clinical Science book series (BLOOMSBURY)

Abstract

The arthropod-borne protozoan parasitoses caused by Plasmodium sp have produced incalculable human misery, morbidity, and mortality since antiquity; it is clear that Plasmodium sp is related to the coccidia (Chap. 4) (Bruce-Chwatt 1988a), and that the primate-vector cycle was established around 30 million years ago. It seems certain that early man, in the cradle of civilization of Africa (Stringer 1988; Stringer and Andrews 1988), must have been subjected to this group of infections. ‘Malaria’, which replaced the older term ague during the eighteenth century and is derived from the Italian description mal aria (poisonous air), is not a single disease. Human infection by four separate protozoan parasites belonging to the genus Plasmodium (which probably evolved from intestinal coccidia millions of years ago), presents as four diverse and characteristic clinical entities (Spencer and Strickland 1984; Bruce-Chwatt 1985; Haworth 1987; Cook 1989a). That produced by P falciparum causes an acute and potentially lethal illness (‘malignant tertian’ malaria, in the older terminology) while at the opposite end of the spectrum, P malariae produces a very chronic infection that may continue, often without serious morbidity, for 50 years or more (Table 1.1.). Diseases with intermediate clinical presentations result from infection with P vivax and P ovale; though neither is characteristically associated with acute mortality or great chronicity, both result in considerable subacute morbidity.

Keywords

Falciparum Malaria Acquire Immune Deficiency Syndrome Cerebral Malaria Falciparum Infection Human Malaria 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aikawa M (1988) Human cerebral malaria. Am J Trop Med Hyg 39: 3–10PubMedGoogle Scholar
  2. Avidor B, Golenser J, Schutte CHJ, Cox GA, Isaacson M, Sulitzeanu D (1987) A radioimmunoassay for the diagnosis of malaria. Am J Trop Med Hyg 37: 225–229PubMedGoogle Scholar
  3. Bajpai R, Dutta GP, Vishwakarma RA (1989) Blood shizontocidal activity of a new antimalarial drug, arteether (α/β), against Plasmodium knowlesi in rhesus monkeys. Trans R Soc Trop Med Hyg 83: 484PubMedGoogle Scholar
  4. Ballou WR, Hoffman, SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, Wasserman GF, Reeve P, Diggs CL, Chulay JD (1987) Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1: 1277–1281PubMedGoogle Scholar
  5. Bradley AK, Greenwood BM, Greenwood AM, Marsh, K, Byass P, Tulloch S, Hayes R (1986) Bed-nets (mosquito-nets) and morbidity from malaria. Lancet 2: 204–207PubMedGoogle Scholar
  6. Brandicourt O, Druilhe P, Brasseur P, Turk P, Diquet B, Datry A, Danis M, Gentilini M (1986) High level of chloroquine resistance in seven Plasmodium falciparum malaria cases from the Congo and Gabon. Trans R Soc Trop Med Hyg 80: 906–907PubMedGoogle Scholar
  7. Bras J le, Deloron P, Charmot G (1983) Dichlorquinazine (a 4-aminoquinoline) effective in vitro against chloroquine-resistant Plasmodim falciparum. Lancet 1: 73–74PubMedGoogle Scholar
  8. Bras J le, Hatin I, Bouree P, Coco-Cianci O, Garin J-P, Rey M, Charmot G, Roue R (1986) Chloroquine-resistant falciparum malaria in Benin. Lancet 2: 1043–1044PubMedGoogle Scholar
  9. Brasseur P, Druilhe P, Kouamouo J, Moyou SR (1987a) Emergence of Plasmodium falciparum chloroquine resistance in the Sahel part of West Africa. Trans R Soc Trop Med Hyg 81: 162–163PubMedGoogle Scholar
  10. Brasseur P, Pathe-Diallo M, Druilhe P (1987b) Low sensitivity to chloroquine and quinine of Plasmodium falciparum isolates from Guinea in March 1986. Am J Trop Med Hyg 37:452–454PubMedGoogle Scholar
  11. Brook MG, Karet F, Lewis DA, Uriel A, Weir WRC (1989) Interpretation of blood films in diagnosis of malaria. Lancet ii:619Google Scholar
  12. Bruce-Chwatt LJ (1983) Malaria and pregnancy. Br Med J 286: 1457–1458Google Scholar
  13. Bruce-Chwatt LJ (1985) Essential malariology, 2nd edn. Heinemann, London, pp 51–72, 210–260Google Scholar
  14. Bruce-Chwatt LJ (1987a) From Laveran’s discovery to DNA probes: new trends in diagnosis of malaria. Lancet 2: 1509–1511PubMedGoogle Scholar
  15. Bruce-Chwatt LJ (1987b) The challenge of malaria vaccine: trials and tribulations. Lancet 1: 371–373PubMedGoogle Scholar
  16. Bruce-Chwatt LJ (1988a) History of malaria from prehistory to eradication. In: Wernsdorfer WH, McGregor I (eds) Malaria: principles and practice of malariology. Churchill Livingstone, Edinburgh, pp 1–59Google Scholar
  17. Bruce-Chwatt LJ (1988b) Three hundred and fifty years of the Peruvian fever bark. Br Med J 296: 1486–1487Google Scholar
  18. Bruce-Chwatt LJ (1988c) Cinchona and its alkaloids: 350 years. NY State J Med 88: 318–322Google Scholar
  19. Burnham G, Harries A, Macheso A, Wirima J, Molyneux M (1989) Chloroquine-induced pruritus in Malawi: lack of association with onchocerciasis. Trans R Soc Trop Med Hyg 83: 527–528PubMedGoogle Scholar
  20. Campbell GH, Brandling-Bennett AD, Roberts JM, Collins FH, Kaseje DCO, Barber AM, Turner A (1987) Detection of antibodies in human sera to the repeating epitope of the circumsporozoite protein of Plasmodium falciparum using the synthetic peptide (NANP)3 in an enzyme-linked immunosorbent assay ( ELISA ). Am J Trop Med Hyg 37: 17–21Google Scholar
  21. Chanthavanich P, Looaressuwan S, White NJ, Warrell DA, Warrell MJ, DiGiovanni JH, Bredow J. von (1985) Intragastric mefloquine is absorbed rapidly in patients with cerebral malaria. Am J Trop Med Hyg 34: 1028–1036PubMedGoogle Scholar
  22. Childs GE, Haüsler B, Milhous W, Chen C, Wimonwattrawatee T, Pooyindeessss N, Boudreau EF (1988) In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. Am J Trop Med Hyg 38: 24–29PubMedGoogle Scholar
  23. Chiodini PL, Somerville M, Salam I, Tubbs HR, Wood MJ, Ellis CJ (1985) Exchange transfusion in severe falciparum malaria. Trans R Soc Tro Med Hyg 79: 865–866Google Scholar
  24. Collignon P, Hehir J, Mitchell D (1989) Successful treatment of falciparum malaria in pregnancy with mefloquine. Lancet 1: 967PubMedGoogle Scholar
  25. Cook GC (1980) The tropical splenomegaly syndrome and other splenic diseases in the tropics. In: Tropical gastroenterology. Oxford University Press, Oxford, pp 205–221Google Scholar
  26. Cook GC (1986a) Plasmodium falciparum infection: problems in prophylaxis and treatment in 1986. Q J Med 61:1091–1115Google Scholar
  27. Cook GC (1986b) Serious problems with antimalarial drugs. J Infect 13: 1–4PubMedGoogle Scholar
  28. Cook GC (1988a) Prevention and treatment of malaria. Lancet 1: 32–37PubMedGoogle Scholar
  29. Cook GC (1988b) Chemotherapy of parasitic infections. Curr Opin Infect Dis 1: 423–438Google Scholar
  30. Cook GC (1988c) Malaria prophylaxis and treatment: present and future. Curr Med Lit: Infect Dis 2: 1–5Google Scholar
  31. Cook GC (1989a) The great malaria problem: where is the light at the end of the tunnel? J Infect 18: 1–10PubMedGoogle Scholar
  32. Cook GC (1989b) The great malaria problem. Natl Med J India 2: 57Google Scholar
  33. Cook GC (1990) Hepatic structure and function in experimental and human malaria. In: Bianchi L (ed) Infectious diseases of the liver. MTP Press Lancaster (in press)Google Scholar
  34. Coulaud JP, Bras J le, Matheron S, Moriniere B, Saimot AG, Rossignol JF (1986) Treatment of imported cases of falciparum malaria in France with halofantrine. Trans R Soc Trop Med Hyg 80: 615–617PubMedGoogle Scholar
  35. Cowden WB, Butcher GA, Hunt NH, Clark IA, Yoneda F (1987) Antimalarial activity of a riboflavin analog against Plasmodium vinckei in vivo and Plasmodium falciparum in vitro. Am J Trop Med Hyg 37: 495–500PubMedGoogle Scholar
  36. Cox FEG (1988a) Vaccine development: which way for malaria? Nature 331: 486–487PubMedGoogle Scholar
  37. Cox FEG (1988b) Malaria vaccines: the shape of things to come. Nature 333: 702PubMedGoogle Scholar
  38. Crane GG (1986) Hyperreactive malarious splenomegaly (tropical splenomegaly syndrome). Parasitol Today 2: 4–9PubMedGoogle Scholar
  39. Crane GG, Gardner A, Hudson P, Hudson B, Voller A (1977) Malarial antibodies in tropical splenomegaly syndrome in Papua New Guinea. Trans R Soc Trop Med Hyg 71: 308–314PubMedGoogle Scholar
  40. Deloron P, Le Bras J, Savel J, Coulaud JP (1987) Antibodies to the PF155 antigen of Plasmodium falciparum: measurement by cell-ELISA and correlation with expected immune protection. Am J Trop Med Hyg 37: 22–26PubMedGoogle Scholar
  41. DeSilva HJ, Goonetilleke AKE, Senaratna N, Ramesh N, Jayawickrama US, Jayasinghe KSA, Amarasekera LR (1988) Skeletal muscle necrosis in severe falciparum malaria. Br Med J 296: 1039Google Scholar
  42. Dutta P, Pinto J, Rivlin R (1985) Antimalarial effects of riboflavin deficiency. Lancet 2: 1040–1043PubMedGoogle Scholar
  43. Editorial (1983) Malaria in pregnancy. Lancet 2: 84–85Google Scholar
  44. Editorial (1985) Plasmodium falciparum: a major health hazard to Africans and Asians returning home. Lancet 2: 871–872Google Scholar
  45. Editorial (1989) Halofantrine in the treatment of malaria. Lancet 2: 537–538Google Scholar
  46. Edstein MD, Veenendaal JR, Rieckmann KH, O’Donoghue M (1988) Failure of dapsone/ pyrimethamine plus chloroquine against falciparum malaria in Papua New Guinea. Lancet 1: 237PubMedGoogle Scholar
  47. Elford BC, Roberts MF, Phillipson JD, Wilson RJM (1987) Potentiation of the antimalarial activity of qinghaosu by methoxylated flavones. Trans R Soc Trop Med Hyg 81: 434–436PubMedGoogle Scholar
  48. Ellis CJ (1988) Death despite malaria prophylaxis. Br Med J 296: 952Google Scholar
  49. Esposito R (1985) Emetine and metronidazole as antimalarial drugs. Lancet 2: 784PubMedGoogle Scholar
  50. Fitch CD (1986) Antimalarial schizontocides: ferriprotoporphyrin IX interaction hypothesis. Parasitol Today 2: 330–331PubMedGoogle Scholar
  51. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC (1988) Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine-pyrimethamine. Br Med J 296: 820–822Google Scholar
  52. Garnham PCC (1988) Hypnozoites and ‘relapses’ in Plasmodium vivax and in vivax-like malaria. Trop Geog Med 40: 187–195Google Scholar
  53. Gasquet M, Atouk A, Samat A, Timon-David P, Viala A (1987) In vitro chemosensitivity of Plasmodium falciparum to four chloroquine derivatives. Ann Trop Med Parasitol 81: 355–358PubMedGoogle Scholar
  54. Geary TG, Jensen JB (1983) Effects of antibiotics on Plasmodium falciparum in vitro. Am J Trop Med Hyg 32: 221–225PubMedGoogle Scholar
  55. Geary TG, Jensen JB (1986) Protozoan infections of man: malaria. In: Campbell WC, Rew RS (eds) Chemotherapy of parasitic diseases. Plenum Press, New York, pp 87–114Google Scholar
  56. Ginsburg H (1988) Effect of calcium antagonists on malaria susceptibility to chloroquine. Parasitol Today 4: 209–211PubMedGoogle Scholar
  57. Gubler J (1988) Sulfadoxine-pyrimethamine resistant malaria from west or central Africa. Br Med J 296: 433Google Scholar
  58. Hadley TJ, Chulay JD (1988) Perspectives on immunization against malaria. In: Leech JH, Sande MA, Root RK (eds) Parasitic infections. Churchill Livingstone, New York and Edinburgh, pp 285–310Google Scholar
  59. Harinasuta T, Bunnag D, Lasserre R, Leimer R, Vinijanont S (1985) Trials of mefloquine in vivax and of mefloquine plus ‘Fansidar’ in falciparum malaria. Lancet 1: 885–888PubMedGoogle Scholar
  60. Hatton CSR, Peto TEA, Bunch C, Pasvol G, Russell SJ, Singer CRJ, Edwards G, Winstanley P (1986) Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1: 411–414PubMedGoogle Scholar
  61. Haworth J (1987) Malaria in man: its epidemiology, clinical aspects and control. Trop Dis Bull 84: R1–R51Google Scholar
  62. Hernborg A (1985) Stevens-Johnson syndrome after mass prophylaxis with sulfadoxine for cholera in Mozambique. Lancet 2: 1072–1073PubMedGoogle Scholar
  63. Higgins DG, McConnell DJ, Sharp PM (1989) Malarial proteinase? Nature 340: 604PubMedGoogle Scholar
  64. Hoffman SL (1986) Treatment of malaria. In: Strickland GT (ed) Clinics in tropical medicine and communicable diseases, vol 1. Saunders, Philadelphia, pp 171–224Google Scholar
  65. Hoffman SL, Wistar R, Ballou WR, Hollingdale MR, Wirtz RA, Schneider I, Marwoto HA, Hockmeyer WT (1986) Immunity of malaria and naturally acquired antibodies to the circumsporozoite protein of Plasmodium falciparum. N Engl J Med 315: 601–606PubMedGoogle Scholar
  66. Holmberg M, Shenton FC, Franzén L, Janneh K, Snow RW, Pettersson U, Wigzell H, Greenwood BM (1987) Use of a DNA hybridization assay for the detection of Plasmodium falciparum in field trials. Am J Trop Med Hyg 37: 230–234PubMedGoogle Scholar
  67. Hutchinson DBA, Whiteman PD, Farquhar JA (1986) Agranulocytosis associated with Maloprim: a review of cases. Hum Toxicol 5: 221–227PubMedGoogle Scholar
  68. Jackson DV, Marcarelli P, Segal G (1987) Chloroquine-resistant Plasmodium falciparum malaria in West Africa. MMWR 36: 13–14Google Scholar
  69. Jacobs GH, Oduola AM J, Kyle DE, Milhous WK, Martin SK, Aikawa M (1988) Ultrastructural study of the effects of chloroquine and verapamil on Plasmodium falciparum. Am J Trop Med Hyg 39: 15–20PubMedGoogle Scholar
  70. James RF (1985) Malaria treated with emetine or metronidazole. Lancet 2: 498PubMedGoogle Scholar
  71. Jiang J-B, Li G-Q, Guo X-B, Kong YC, Arnold K (1982) Antimalarial activity of mefloquine and qinghaosu. Lancet 2: 285–288PubMedGoogle Scholar
  72. Katongole-Mbidde E, Banura C, Kizito A (1988) Blackwater fever caused by Plasmodium vivax infection in the acquired immune deficiency syndrome. Br Med J 296: 827Google Scholar
  73. Khusmith S, Tharavanij S, Chongsa-Nguan M, Vejvongvarn C, Kasemsuth R (1988) Field applications of an immunoradiometric assay for the detection of Plasmodium falciparum antigen in a population in a malaria endemic area in Thailand. Am J Trop Med Hyg 38: 1–6Google Scholar
  74. Kibukamusoke JW (1984) Quartan malaria nephropathy. In: Kibukamusoke JW (ed) Tropical nephrology. Citforge, Canberra, pp 58–75Google Scholar
  75. Kofi Ekue JM, Simooya OO, Sheth UK, Wernsdorfer WH, Njelesani EK (1985) A double-blind clinical trial of a combination of mefloquine, sulfadoxine and pyrimethamine in symptomatic falciparum malaria. Bull WHO 63: 339–343Google Scholar
  76. Krishna S, Davis TME, Chan PCY, Wells RA, Robson KJH (1988) Ciprofloxacin and malaria. Lancet 1: 1231–1232PubMedGoogle Scholar
  77. Krogstad DJ, Schlesinger PH (1987) The basis of antimalarial action: non-weak base effects of chloroquine on acid vesicle pH. Am J Trop Med Hyg 36: 213–220PubMedGoogle Scholar
  78. Kwiatkowski D, Greenwood BM (1989) Why is malaria fever periodic? A hypothesis. Parasitol Today 5: 264–266PubMedGoogle Scholar
  79. Larrey D, Castot A, Pessayre D, Merigot P, Machayekhy J-P, Feldmann G, Lenoir A, Rueff B, Benhamou J-P (1986) Amodiaquine-induced hepatitis: a report of seven cases. Ann Intern Med 104: 801–803PubMedGoogle Scholar
  80. Laveran A (1881) Un nouveau parasite trouvé dans le sang des malades atteints de fièvre palustre. Bull Soc Med Hop Paris (Mem) 17: 158–164Google Scholar
  81. Lee PS, Lau EYL (1988) Risk of acute non-specific upper respiratory tract infections in healthy men taking dapsone-pyrimethamine for prophylaxis against malaria. Br Med J 296: 893–895Google Scholar
  82. Lim TS (1988) A sensitive malaria immunoperoxidase assay for the detection of Plasmodium falciparum antibody. Am J Trop Med Hyg 38: 255–257PubMedGoogle Scholar
  83. Lobel HO, Campbell CC (1986) Malaria prophylaxis and distribution of drug resistance. In: Strickland GT (ed) Clinics in tropical medicine and communicable diseases, vol 1. Saunders, Philadelphia, pp 225–242Google Scholar
  84. Lobel HO, Campbell CC, Pappaioanou M, Huong AY (1987) Use of prophylaxis for malaria by American travelers to Africa and Haiti. JAMA 257: 2626–2627PubMedGoogle Scholar
  85. Looareesuwan S, Warrell DA, White NJ, Chanthavanich P, Warreil MJ, Chantaratherakitti S, Changswek S, Chongmankongcheep L, Kanchanaranya C (1983) Retinal haemorrhage, a common sign of prognostic significance in cerebral malaria. Am J Trop Med Hyg 32: 911–915PubMedGoogle Scholar
  86. Looareesuwan S, Phillips RE, White NJ, Karbwang J, Benjasurat Y, Attanath P, Warrell DA (1985a) Intravenous amodiaquine and oral amodiaquine/erythromycin in the treatment of chloroquine-resistant falciparum malaria. Lancet 2: 805–808PubMedGoogle Scholar
  87. Looareesuwan S, Phillips RE, White NJ, Kietinun S. Karbwang J, Rackow C, Turner RC, Warrell DA (1985b) Quinine and severe falciparum malaria in late pregnancy. Lancet 2: 4–8PubMedGoogle Scholar
  88. Looareesuwan S, White NJ, Chittamas S, Bunnag D, Harinasuta T (1987) High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet 2: 1052–1055PubMedGoogle Scholar
  89. Lumsden WHR (1989) Sweating it out. Br Med J 299: 1341Google Scholar
  90. Malaria Reference Laboratory (1989) Prophylaxis against malaria for travellers from the United Kingdom. Br Med J 299: 1087–1089Google Scholar
  91. Manson P (1900) Experimental proof of the mosquito-malaria theory. Br Med J 2: 949–951PubMedGoogle Scholar
  92. Manson-Bahr PEC, Bell DR (1987) Malaria and babesiosis. In: Manson’s tropical diseases, 19th edn. Bailliere, Tindall, London, 3–51Google Scholar
  93. Martin SK, Oduola AMJ, Milhous WK (1987) Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235: 899–901PubMedGoogle Scholar
  94. Mashaal H (1986) Malaria in infants and children. In: Clinical malariology 1986. Japan: Southeast Asian Medical Information Center, Japan, 126–40Google Scholar
  95. McLaughlin GL, Breman JG, Collins FH, Schwartz IK, Brandling-Bennett AD, Sulzer AJ, Collins WE, Skinner JC, Ruth JL, Andrysiak PM, Kaseje DCO, Campbell GH (1987) Assessment of a synthetic DNA probe for Plasmodium falciparum in African blood specimens. Am J Trop Med Hyg 37: 27–36PubMedGoogle Scholar
  96. Meek SR, Doberstyn EB, Gaüzere BA, Thanapanich C, Nordlander E, Phuphaisan S (1986) Treatment of falciparum malaria with quinine and tetracycline or combined mefloquine/sulfadoxine/pyrimethamine on the Thai-Kampuchean border. Am J Trop Med Hyg 35: 246–250PubMedGoogle Scholar
  97. Midgley JM, Keter DW, Phillipson JD, Grant S, Warhurst DC (1988) Quinolones and multiresistant Plasmodium falciparum. Lancet 2: 281PubMedGoogle Scholar
  98. Miller KD, Lobel HO, Pappaioanou M, Patchen LC, Churchill FC (1986a) Failures of combined chloroquine and Fansidar prophylaxis in American travellers to East Africa. J Infect Dis 154: 689–691PubMedGoogle Scholar
  99. Miller KD, Lobel HO, Satriale RF, Kuritsky JN, Stern R, Campbell CC (1986b) Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine ( Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 35: 451–458Google Scholar
  100. Miller KD, Greenberg AE, Campbell CC (1989) Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. N Engl J Med 321: 65–70PubMedGoogle Scholar
  101. Miller LH (1986) Research in malaria vaccines. N Eng J Med 315: 640–641Google Scholar
  102. Miller LH (1988) Malaria: effective vaccine for humans? Nature 332: 109–110PubMedGoogle Scholar
  103. Molyneux ME, Looareesuwan S, Menzies IS, Grainger SL, Phillips RE, Wattanagoon Y, Thompson RPH, Warrell DA (1989a) Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. Am J Trop Med Hyg 40: 470–476PubMedGoogle Scholar
  104. Molyneux ME, Taylor TE, Wirima JJ, Harper G (1986b) Effect of rate of infusion of quinine on insulin and glucose responses in Malawian children with falciparum malaria. Br Med J 299: 602–603Google Scholar
  105. Myint PT, Shwe T (1987) A controlled clinical trial of artemether (qinghaosu derivative) versus quinine in complicated and severe falciparum malaria. Trans R Soc Trop Med Hyg 81: 559–561Google Scholar
  106. Nahlen BL, Akintunde A, Alakija T, Ngugen-Dinh P, Ogunbode O, Edungbola LD, Adetoro O, Breman JG (1989) Lack of efficacy of pyrimethamine prophylaxis in pregnant Nigerian women. Lancet 2: 830–834PubMedGoogle Scholar
  107. Neeguaye J (1986) In vivo chloroquine-resistant falciparum malaria in western Africa. Lancet 1: 153Google Scholar
  108. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J (1986) Amodiaquine induced agranulocytosis and liver damage. Br Med J 292: 721–723Google Scholar
  109. Nevill CG, Watkins WM, Carter JY, Munafu CG (1988) Comparison of mosquito nets, proguanil hydrochloride, and placebo to prevent malaria. Br Med J 297: 401–403Google Scholar
  110. Nguyen-Dinh P, Greenberg AE, Ryder RW, Mann JM (1987a) Absence of association between HIV seropositivity and Plasmodium falciparum malaria in Kinshasa, Zaire. Abstracts of Third International Conference on AIDS, Washington, DC, p 22Google Scholar
  111. Nguyen-Dinh P, Berzins K, Collins WE, Wahlgren M, Udomsangpetch R, Perlmann P (1987b) Antibodies to PF155, a major antigen of Plasmodium falciparum: longitudinal studies in humans. Am J Trop Med Hyg 37: 501–505PubMedGoogle Scholar
  112. Nickell SP, Scheibel LW, Cole GA (1982) Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Infect Immunol 37: 1093–1100Google Scholar
  113. Nussenzweig V, Nussenzweig RS (1986) Development of a sporozoite malaria vaccine. Am J Trop Med Hyg 35: 678–688PubMedGoogle Scholar
  114. Oduola AM J, Milhous WK, Salako LA, Walker O, Desjardins RE (1987) Reduced in-vitro susceptibility to mefloquine in west African isolates of Plasmodium falciparum. Lancet 2: 1304–1305PubMedGoogle Scholar
  115. Onori E, Phan VT (1986) Is Plasmodium falciparum resistance to chloroquine reversible in absence of drug pressure? Lancet 1: 319PubMedGoogle Scholar
  116. Pang LW, Linsomwong N, Boudreau EF, Singharaj P (1987) Doxycycline prophylaxis for falciparum malaria. Lancet 1: 1161–1164PubMedGoogle Scholar
  117. Pappaioanou M, Fishbein DB, Dreesen DW, Schwartz IK, Campbell GH, Sumner JW, Patchen LC, Brown WJ (1986) Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 314: 280–284PubMedGoogle Scholar
  118. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo LA, Ponton G, Trujillo G (1988) A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332: 158–161PubMedGoogle Scholar
  119. Peters W (1987a) Chemotherapy and drug resistance in malaria, 2nd edn. Academic Press, Orlando and London, p 1100Google Scholar
  120. Peters W (1987b) How to prevent malaria. Trop Doct 17: 1–3PubMedGoogle Scholar
  121. Peters W, Ekong R, Robinson BL, Warhurst DC, Pan X-Q (1989) Antihistaminic drugs that reverse chloroquine resistance in Plasmodium falciparum. Lancet 2: 334–335PubMedGoogle Scholar
  122. Petersen C, Leech JH (1988) Diagnosis, treatment, and prevention of malaria due to Plasmodium falciparum. In: Leech JH, Sande MA, Root RK (eds) Parasitic infections. Churchill Livingstone, New York and Edinburgh, pp 311–326Google Scholar
  123. Peto TEA, Gilks CF (1986) Strategies for the prevention of malaria in travellers: comparison of drug regimens by means of risk-benefit analysis. Lancet 1: 1256–1261PubMedGoogle Scholar
  124. Phillips RE, Warrell DA, White NJ, Looareesuwan S, Karbwang J (1985) Intravenous quinidine for the treatment of severe falciparum malaria: clinical and pharmacokinetic studies. N Engl J Med 312: 1273–1278PubMedGoogle Scholar
  125. Phillips RE, Looareesuwan S, Warrell DA, Lee SH, Karbwang J, Warrell MJ, White NJ, Swasdichai C, Weatherall DJ (1986a) The importance of anaemia in cerebral and uncomplicated falciparum malaria: role of complications, dyserythropoiesis and iron sequestration. Q J Med 58: 305–323PubMedGoogle Scholar
  126. Phillips RE, Warrell DA, Edwards G, Galagedera Y, Theakstone RDG, Abeysekera DTDJ, Dissanayaka P (1986b) Divided dose intramuscular regimen and single dose subcutaneous regimen for chloroquine: plasma concentrations and toxicity in patients with malaria. Br Med J 293: 13–16Google Scholar
  127. Phillips-Howard PA, Bradley DJ, Blaze M, Hum M (1988) Malaria in Britain: 1977–86. Br Med J 296: 245–248Google Scholar
  128. Phillips-Howard PA, Behrens RH, Dunlop J (1989) Stevens-Johnson Syndrome due to pyrimetha-mine/sulfadoxine during presumptive self-therapy of malaria. Lancet 2: 803–804PubMedGoogle Scholar
  129. Public Health Laboratory Service Malaria Reference Laboratory (1984) Prevention of malaria in pregnancy and early childhood. Br Med J 289: 1296–1297Google Scholar
  130. Reisinger EC, Horstmann RD, Dietrich M (1989) Tolerance of mefloquine alone and in combination with sulfadoxine-pyrimethamine in the prophylaxis of malaria. Trans R Soc Trop Med Hyg 83: 474–477PubMedGoogle Scholar
  131. Rhodes EGH, Ball J, Franklin IM (1986) Amodiaquine induced agranulocytosis: inhibition of colony growth in bone marrow by antimalarial agents. Br Med J 292: 717–718Google Scholar
  132. Rieckmann KH (1987) Tetracycline prophylaxis for malaria. Lancet 2: 507–508PubMedGoogle Scholar
  133. Rieckmann KH, Davis DR, Hutton DC (1989) Plasmodium vivax resistance to chloroquine? Lancet 2: 1183–1184Google Scholar
  134. Rickman LS, Long GW, Hoffman SL (1989a) Rapid diagnosis of malaria. Lancet 1: 1271PubMedGoogle Scholar
  135. Rickman LS, Long GW, Oberst R, Cabanban A, Sangalang R, Smith JI, Chulay JD, Hoffman SL (1989b) Rapid diagnosis of malaria by acridine orange staining of centrifuged parasites. Lancet 1: 68–71PubMedGoogle Scholar
  136. Ristic M (ed) (1988) Babesiosis of domestic animals and man. CRC Press, Boca Raton, Florida, p 255Google Scholar
  137. Rizzo F, Morandi N, Riccio G, Ghiazza G, Caravelli P (1989) Unusual transmission of falciparum malaria in Italy. Lancet 1: 555–556PubMedGoogle Scholar
  138. Rosenberg R, Wirtz RA, Lanar DE, Sattabongkot J, Hall T, Waters AP, Prasittisuk C (1989) Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science 245: 973–976PubMedGoogle Scholar
  139. Ross R (1897) On some peculiar pigmented cells found in two mosquitos fed on malarial blood. Br Med J 2: 1786–1788PubMedGoogle Scholar
  140. Ross (1898) The role of the mosquito in the evolution of the malarial parasite. Lancet 2: 488–489Google Scholar
  141. Ross R (1988) The great malaria problem and its solution: from the memoirs of Ronald Ross. Keynes Press, London, p 236Google Scholar
  142. Ruebush TK (1984) Babesiosis. In: Strickland GT (ed) Hunter’s tropical medicine, 6th edn. Saunders, Philadelphia, pp 608–611Google Scholar
  143. Saarinen M, Thoren E, Iyambo N, Carlstedt A, Shinyafa L, Fernanda M, Paajanen H, Paajanen K, Indongo I, Rombo L (1987) Mass proguanil prophylaxis. Lancet 1: 985–986PubMedGoogle Scholar
  144. Schofield L, Villaquiran J, Ferreira A, Schellekens H, Nussenzweig R, Nussenzweig V (1987) Interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664–666PubMedGoogle Scholar
  145. Shortt HE, Garnham PCC (1948) Demonstration of a persisting exo-erythrocytic cycle in Plasmodium cynomolgi and its bearing on the production of relapses. Br Med J 1: 1225–1228PubMedGoogle Scholar
  146. Shortt HE, Garnham PCC, Covell G, Shute PG (1948) The pre-erythrocytic stage of human malaria. Plasmodium vivax. Br Med J 1: 547PubMedGoogle Scholar
  147. Shwe T, Myint PT, Myint W, Htut Y, Soe L, Thwe M (1989) Clinical studies on treatment of cerebral malaria with artemether and mefloquine. Trans R Soc Trop Med Hyg 83: 489PubMedGoogle Scholar
  148. Simon F, Bras J le, Gaudebout C, Girard PM (1988) Reduced sensitivity of Plasmodium falciparum to mefloquine in west Africa. Lancet 1: 467–468PubMedGoogle Scholar
  149. Simooya OO, Mwendapole RM, Siziya S, Fleming AF (1988) Relation between falciparum malaria and HIV seropositivity in Ndola, Zambia. Br Med J 297: 30–31Google Scholar
  150. Slutsker L, Breman JG, Campbell CC (1988) Strategies for control of malaria in Africa. Lancet 2: 283PubMedGoogle Scholar
  151. Sowunmi A, Walker O, Salako LA (1989) Pruritus and antimalarial drugs in Africans. Lancet 2: 213PubMedGoogle Scholar
  152. Spencer HC, Strickland GT (1984) Malaria. In: Strickland GT (ed) Hunter’s tropical medicine, 6th edn. Saunders, Philadelphia, pp 516–552Google Scholar
  153. Spielman A, Perrone JB (1989) Rapid diagnosis of malaria. Lancet 1: 727PubMedGoogle Scholar
  154. Stemberger H, Leimer R, Wiedermann G (1984) Tolerability of long-term prophylaxis with Fansidar: a randomized double-blind study in Nigeria. Acta Trop (Basel) 41: 391–399Google Scholar
  155. Stringer C (1988) The dates of Eden. Nature 331: 565–566PubMedGoogle Scholar
  156. Stringer CB, Andrews P (1988) Genetic and fossil evidence for the origin of modern humans. Science 239: 1263–1268PubMedGoogle Scholar
  157. Stuiver PC, Ligthelm RJ, Goud TJLM (1989) Acute psychosis after mefloquine. Lancet 2: 282PubMedGoogle Scholar
  158. Taylor DN, Pitarangsi C, Echeverria P, Diniega BM (1988) Campylobacter enteritis during doxycycline prophylaxis for malaria in Thailand. Lancet 2: 578–579Google Scholar
  159. Thaithong S, Suebsaeng L, Rooney W, Beale GH (1988) Evidence of increased chloroquine sensitivity in Thai isolates of Plasmodium falciparum. Trans R Soc Trop Med Hyg 82: 37–38PubMedGoogle Scholar
  160. Ti T-Y, Jacob E, Wee YJ (1987) The effect of dapsone-pyrimethamine on immunoglobulin concentrations in malaria chemoprophylaxis. Trans R Soc Trop Med Hyg 81: 245–246PubMedGoogle Scholar
  161. Trager W (1989) Erythrocyte knobs and malaria. Nature 340: 352PubMedGoogle Scholar
  162. Udezue EO (1985) Persistence of malarial antibody in Nigerian children born in the UK and its clinical relevance. Trans R Soc Trop Med Hyg 79: 427–429PubMedGoogle Scholar
  163. Udomsangpetch R, Aikawa M, Berzins K, Wahlgren M, Perlmann P (1989) Cytoadherence of knobless Plasmodium falciparum-infected erythrocytes and its inhibition by a human monoclonal antibody. Nature 338: 763–765PubMedGoogle Scholar
  164. Wakeel El S El, Homeida MMA, Ali HM, Geary TG, Jensen JB (1985) Clindamycin for the treatment of falciparum malaria in Sudan. Am J Trop Med Hyg 34: 1065–1068PubMedGoogle Scholar
  165. Warhurst DC (1986a) Antimalarial drugs: mode of action and resistance. J Antimicrob Chemother 18 [suppl B]: 51–59PubMedGoogle Scholar
  166. Warhurst DC (1986b) Antimalarial schizontocides: why a permease is necessary. Parasitol Today 2: 331–334PubMedGoogle Scholar
  167. Warhurst DC (1987) Antimalarial drugs: an update. Drugs 33: 50–65PubMedGoogle Scholar
  168. Warhurst DC (1988) Mechanism of chloroquine resistance in malaria. Parasitol Today 4: 211–213PubMedGoogle Scholar
  169. Warrell DA (1987) Pathophysiology of severe falciparum malaria in man. Parasitology 94: S53–S76PubMedGoogle Scholar
  170. Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intaraprasert R, Bunnag D, Harinasuta T (1982) Dexamethasone proves deleterious in cerebral malaria: a double-blind trial in 100 comatose patients. N Engl J Med 306: 313–319PubMedGoogle Scholar
  171. Waters AP, McCutchan TF (1989) Rapid, sensitive diagnosis of malaria based on ribosomal DNA. Lancet 1: 1343–1346PubMedGoogle Scholar
  172. Watkins WM, Branding-Bennett AD, Oloo AJ, Howells RE, Gilles HM, Koech DK (1987) Inadequacy of chlorproguanil 20 mg per week as chemoprophylaxis for falciparum malaria in Kenya. Lancet 1: 125–128PubMedGoogle Scholar
  173. Watkins WM, Oloo JA, Lury JD, Mosoba M, Kariuki D, Mjomba M, Koech DK, Gilles HM (1988) Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. Lancet 2: 247–250PubMedGoogle Scholar
  174. Wattanagoon Y, Phillips RE, Warreil DA, Silamut K, Looareesuwan S, Nagachinta B, Back DJ (1986) Intramuscular loading dose of quinine for falciparum malaria: pharmacokinetics and toxicity. Br Med J 293: 11–13Google Scholar
  175. Webster HK, Ho M, Looareesuwan S, Pavanand K, Wattanagoon Y, Warreil DA, Hockmeyer WT (1988) Lymphocyte responsiveness to a candidate malaria sporozoite vaccine (R32tet32) of individuals with naturally acquired Plasmodium falciparum malaria. Am J Trop Med Hyg 38: 37–41PubMedGoogle Scholar
  176. Wernsdorfer WH, MacGregor I (eds) (1988) Malaria: principles and practice of malariology (2 vols). Churchill Livingstone, Edinburgh, p 1818Google Scholar
  177. White NJ (1987) Combination treatment for falciparum prophylaxis. Lancet 1: 680–681PubMedGoogle Scholar
  178. White NJ (1988) The treatment of falciparum malaria. Parasitol Today 4: 10–14PubMedGoogle Scholar
  179. White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Chanthavanich P, Bunnag D, Harinasuta T (1983a) Quinine loading dose in cerebral malaria. Am J Trop Med Hyg 32: 1–5PubMedGoogle Scholar
  180. White NJ, Warrell DA, Chanthavanich P, Looareesuwan S, Warrell MJ, Krishna S, Williamson DH, Turner RC (1983b) Severe hypoglycemia and hyperinsulinemia in falciparum malaria. N Engl J Med 309: 61–66PubMedGoogle Scholar
  181. White NJ, Miller KD, Brown J, Marsh K, Greenwood B (1987a) Prognostic value of CSF lactate in cerebral malaria. Lancet 1: 1261PubMedGoogle Scholar
  182. White NJ, Miller KD, Marsh K, Berry CD, Turner RC, Williamson DH, Brown J (1987b) Hypoglycaemia in African children with severe malaria. Lancet 1: 708–711PubMedGoogle Scholar
  183. White NJ, Watt G, Bergqvist Y, Njelesani EK (1987c) Parenteral chloroquine for treating falciparum malaria. J Infect Dis 155: 192–201PubMedGoogle Scholar
  184. Whiteley HE, Everitt JI, Kakoma I, James MA, Ristic M (1987) Pathologic changes associated with fatal Plasmodium falciparum infection in the Bolivian squirrel monkey (Saimiri sciureus boliviensis). Am J Trop Med Hyg 37: 1–8PubMedGoogle Scholar
  185. Whitfield D, Curtis CF, White GB, Targett GAT, Warhurst DC, Bradley DJ (1984) Two cases of falciparum malaria acquired in Britain. Br Med J 289: 1607–1609Google Scholar
  186. Williams A, Lewis DJM (1987) Malaria prophylaxis: postal questionnaire survey of general practitioners in south-east Wales. Br Med J 295: 1449–1452Google Scholar
  187. Win K, Thwe Y, Lwin TT, Win K (1985) Combination of mefloquine with sulfadoxine-pyrimethamine compared with two sulfadoxine-pyrimethamine combinations in malaria chemoprophylaxis. Lancet 2: 694–695PubMedGoogle Scholar
  188. Wirima J, Khoromana C, Molyneux ME, Gilles HM (1988) Clinical trials with halofantrine hydrochloride in Malawi. Lancet 2: 250–252PubMedGoogle Scholar
  189. Wirth DF, Rogers WO, Barker R, Dourado H, Suesebang L, Albuquerque B (1986) Leishmaniasis and malaria: new tools for epidemiologic analysis. Science 234: 975–979PubMedGoogle Scholar
  190. World Health Organisation (1973) Chemotherapy of malaria and resistance to antimalarials. World Health Organisation, Geneva, pp 30–54 (WHO Tech Rep Ser 529 )Google Scholar
  191. World Health Organisation (1987) World malaria situation, 1985. World Health Stat Q 40: 142–170Google Scholar
  192. World Health Organisation (1988) Vaccination certificate requirements and health advice for international travel. WHO, Geneva, p 85Google Scholar
  193. Wright IG, Goodger BV, Clark IA (1988) Immunopathophysiology of Babesia bovis and Plasmodium falciparum infections. Parasitol Today 4: 214–218PubMedGoogle Scholar
  194. Wu L-J, Rabbege JR, Nagasawa H, Jacobs G, Aikawa M (1988) Morphological effects of pyronaridine on malarial parasites. Am J Trop Med Hyg 38: 30–36PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1990

Authors and Affiliations

  • G. C. Cook
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Hospital for Tropical DiseasesUniversity College HospitalUK
  2. 2.St Luke’s Hospital for the ClergyUK
  3. 3.London School of Hygiene and Tropical MedicineUK
  4. 4.Royal Nigerian ArmyNigeria
  5. 5.Makerere UniversityUganda

Personalised recommendations